NeuroSense’s ALS drug PrimeC shows success in phase 2b, eyes final trial
PrimeC has been given an ‘Orphan Drug’ status by the FDA (Food and Drug Administration) and EMA (European Medicines Agency).
Pharmabiz41m
ProMIS Neurosciences begins patient dosing in phase 1b PRECISE-AD trial of PMN310 for Alzheimer’s disease
Massachusetts, Cambridge Saturday, March 1, 2025, 18:00 Hrs [IST] ...